| Reference | Location | Time Period | Study Design | Study Population | Results |
| Magnesium sulphate therapy for eclampsia (Adewole et al., 2000) | Nigeria | 06/1997-10/1998 | Before and after study | n = 21 Pregnant women with eclampsia | Magnesium sulphate was an effective therapy for eclampsia, resulting in no maternal deaths and two complications : one case of oliguria and another case of respiratory distress |
| Oral misoprostol therapy for postpartum hemorrhage (Derman et al., 2006) | India | 09/2002-12/2005 | Randomized, placebo- controlled trial | n = 1620 pregnant women. Oral misoprostol group (n = 812) Placebo group (n = 808) | Oral misoprostol significantly reduced the rate of acute postpartum hemorrhage (from 12% to 6.4%, p < 0.0001) |
| Effectiveness of UADV (uterine artery Doppler velocimetry) and maternal plasma PIGF (placental growth factor) and sVEGFR-1 (soluble vascular endothelial growth factor receptor-1) concentrations as risk markers for the development of severe and/or early onset pre-eclampsia (Espinoza et al., 2007) | Chile | 01/1998-04/2004 | Prospective observational cohort study | n = 3348 pregnant women | Abnormal UADV together with maternal plasma PIGF concentration of <280 pg/mL in the 2nd trimester are risk markers for the development of pre-eclampsia and early onset and/or severe pre-eclampsia. They were associated with an “odds ratio (OR) of 43.8 (95% CI, 18.48 - 103.89) for the development of early onset pre- eclampsia, an OR of 37.4 (95% CI, 17.64 - 79.07) for the development of severe pre-eclampsia, an OR of 8.6 (95% CI, 5.35 - 13.74) for the development of pre-eclampsia” (Espinoza et al., 2007) |
| Impact of effective EmOC (emergency obstetric care) on maternal mortality (Kayongo et al., 2006) | Peru | 2000-2004 | Before and after study | 5 health facilities in Ayacucho, Peru | There was a yearly average of 2980 deliveries among the 5 participating health facilities. Strengthened EmOC resulted in over 50% increased met need for EmOC, lower case fatality rates (1.7% in 2000 to 0.1% in 2004), and reduced maternal deaths (2 deaths in 2004 compared to 9 deaths in 2000) |
| Magnesium sulphate therapy for pre-eclampsia and eclampsia (Noor et al., 2004) | Pakistan | 01/2000-12/2000 | Descriptive study using historical data | n = 133 Pregnant women with pre-eclampsia (n = 80) and eclampsia (n = 53) | Magnesium sulphate reduced maternal deaths. There was one death from severe pre-eclampsia and 8 deaths from eclampsia |
| Accuracy of drape versus visual estimation of postpartum blood loss (Patel et al., 2006) | India | 09/2003-12/2003 | Randomized controlled study | n = 123 Drape estimation group (n = 62); Visual estimation group (n = 61); Pregnant women having vaginal delivery | Visual estimation of blood loss was 33% less than drape estimation, a significant difference (p < 0.001) |
| Impact of trained TBAs (traditional birth attendants) on maternal mortality (Schaider et al., 1999) | Angola | 1994-1998 | Quasi- experimental study using historical comparisons | n = 23,569 TBAs assisted home deliveries. Total of 1133 trained TBAs | Trained TBAs-assisted home deliveries led to a reduction in maternal mortality (maternal mortality associated with trained TBAs = 293 per 100,000 live births. Maternal mortality rate from historical comparisons = 1241 per 100,000 live births) |
| Effects of vitamin A supplementation on maternal mortality (West Jr. et al., 1999) | Nepal | 04/1994-09/1997 | Double blind, cluster randomized, placebo controlled trial | n = 20,119 women became pregnant in the duration of the study. Placebo group (n = 6580 pregnant women) Vitamin A group (n = 7045 pregnant women) B carotene (n = 6494 pregnant women) | Maternal mortality: Placebo group = 704 deaths per 100,000 pregnancies Vitamin A group = 426 deaths per 100,000 pregnancies B carotene group = 361 deaths per 100,000 pregnancies Vitamin A and B carotene groups = 40% (p < 0.04) and 49% (p < 0.01) reduction in maternal mortality respectively |